必瘦站(01830.HK)全年度整體銷售合同額按年跌3.1%
必瘦站(01830.HK)公布由2021年3月底止年度之未經審核最新營運數據顯示,期間整體銷售合同額按年跌3.1%;香港銷售合同額按年跌16%;中國、澳洲及澳門銷售合同額按年則升32.2%。
在香港政府採取防疫措施下,香港所有美容院於期間之下半年內有38.5%的營業日須強制關閉。受到COVID-19疫情的影響,香港銷售合同於下半年內表現按年僅降1.7%,因專科痛症醫療銷售增長貢獻所帶動。
此外,香港以外地區於下半年內的銷售合同按年大增55.3%。增長主要源於中國客戶消費增加及新成立之澳洲業務貢獻所帶動。總體而言,集團於下半年內之銷售合同表現相比去年同期增長12.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.